MedPanel Launches Profiles in Early-Stage Breast Cancer, First in 2005-2006 Series
Cambridge, MA, October 5, 2005 MedPanel, a leader in online medical market intelligence, announces the launch of Profiles in Early-Stage Breast Cancer, the first release in its 2005-2006 Profiles in Oncology series. Profiles is a subscription service delivering four highly detailed, tumor-specific studies on a quarterly basis. Profiles studies evaluate clinical and commercial market opportunities for both current and emerging oncology products. Profiles is designed to provide in-depth analysis for organizations and companies considering the development, acquisition or launch of a novel therapeutic agent. The studies explore best practices, key outcomes measures, unmet medical needs, and future direction of treatment for a given indication while quantifying the trade-offs associated with varying levels of clinical performance on an agent-specific basis. The latest study offers analysis of adjuvant and neoadjuvant treatment of early-stage breast cancer.
Breast cancer is the second leading cause of cancer deaths in women today and is the second most common cancer among women. According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer this year worldwide. The American Cancer Society estimates that in 2005, approximately 211,240 women in the United States will be diagnosed with invasive breast cancer, and it is estimated that 40,410 women will die from breast cancer in the United States this year. However, breast cancer mortality rates have declined in recent years, with the largest decreases seen in younger women. Medical experts attribute the decline in breast cancer deaths to earlier detection and more effective treatments. Though decreased mortality is encouraging, the level of unmet medical need for this indication remains extremely high.
"The insights contained in Profiles in Early-Stage Breast Cancer should prove invaluable to drug makers as they attempt to develop agents with improved performance," said Matt Fearer, MedPane s Senior Vice President of Content Development. Because clients can manipulate the data housed in each Profiles study, they are able to quickly assess and quantify the impact of expected an perhaps more importantl unexpected clinical trial results and potential changes in their clinical development programs."
Dr. Nina Karlin, of UCLA, said, In this era of molecular and individualized medicine, it is important to have interactive platforms that allow for the dissemination and exchange of information gathered in clinical trials. MedPanel expertly provides this platform by facilitating interactive discussions between community oncologists and thought leaders
MedPanel is a medical market intelligence company providing custom and syndicated medical market research exclusively online. MedPane s powerful proprietary methodology and platform enable pharmaceutical, biotechnology, medical device, diagnostics companies, as well as others with an interest in life sciences, to have greater strategic control over the development and commercialization of products, and lower costs overall. Through unparalleled access to clinicians, medical thought leaders and healthcare professionals, and through its interactive, asynchronous approach to medical panels and surveys, MedPanel is able to deliver fast, unbiased, cost-effective and actionable data. MedPanel is a global organization based in Cambridge, Massachusetts.
For more information on Profiles, contact Jim Patton at 617.661.8080 x321, or email firstname.lastname@example.org. For media, contact Kerri Norton at 617.661.8080 x329, or email email@example.com.